RRRevathi Raj

Revathi Raj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Revathi Raj has a total of 155 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • TCR ‐αβ/ CD 19 Depleted Graft Versus T Replete Graft With Post‐Transplant Cyclophosphamide in Children Undergoing Haploidentical Donor Hematopoietic Stem Cell Transplantation for Inborn Errors of Immunity: A Comparative Analysis From India

    by Anuraag Reddy Nalla, Kavitha Ganesan, Vijayshree Muthukumar, Minakshi Balwani, Nithya Seshadri, Krithika Krishnakumar, Ramya Uppuluri, Revathi Raj

    Background: The study aimed to analyze the outcomes of TCRαβ / CD19 ‐depleted and T‐replete graft with post‐transplant cyclophosphamide ( PTCY ) in haploidentical hematopoietic stem cell transplantation ( HSCT ) in inborn errors of immunity ( IEI ). Patients and Methods: We performed a retrospective analysis of children from birth to 18 years of age with IEI who underwent haploidentical HSCT between April 2009 and September 2024, with a minimum follow‐up period of 12 months. Results: A total of 230 children with IEI underwent HSCT in the 15‐year period, where 105 (45%) underwent haploidentical HSCT and were included in the analysis with a follow up period of 0.5 to 170 months. TCR ‐αβ/ CD19 ‐depleted HSCT was done in 65 (62%) children, while T‐replete graft with PTCY was used in 40 (38%) children. There was no significant difference in engraftment rates, acute and chronic graft versus host disease rates between both the cohorts: T‐depleted group—89%, 8.6%, 12% respectively versus T‐replete group—85%, 15%, 17.5% respectively. The 5‐year overall survival was 62% (95% CI : 48%–73%) in the TCR ‐αβ/ CD 19‐depleted cohort in comparison to 54% (95% CI : 48% to 73%) in the PTCY cohort. When the survival was compared in children less than 2 years of age, it was 60% in the TCR ‐αβ/ CD 19 depleted cohort versus 37% in PTCY cohort (p value of 0.001). Conclusion: Survival was superior in the T depleted cohort as compared to the T replete group, with viral reactivation remaining a persisting challenge. Letermovir prophylaxis and memory cell add‐back would be potential strategies to improve survival.


  • Open Access

    Transforming pediatric intensive care unit outcomes in pediatric hematology-oncology and hematopoietic stem cell transplantation through golden hour care in a low- and middle-income country: a 10-year analysis

    by Indira Jayakumar, Milind Ballal, Nalla Anuraag Reddy, Rachit Mehta, Parvathy Menon, Ramya Uppuluri, Revathi Raj, Sandhiya Harikrishnan, Jennifer McArthur

    Objective: To evaluate the impact of a care improvement bundle focused on early intervention, communication, and multidisciplinary collaboration by comparing outcomes across two 5-year periods before and after its implementation. Methods: A single-center, retrospective study was conducted in the Onco-Critical Care pediatric intensive care unit of a tertiary cancer referral hospital in South India, […] ABSTRACT Objective: To evaluate the impact of a care improvement bundle focused on early intervention, communication, and multidisciplinary collaboration by comparing outcomes across two 5-year periods before and after its implementation. Methods: A single-center, retrospective study was conducted in the Onco-Critical Care pediatric intensive care unit of a tertiary cancer referral hospital in South India, […]

  • Open Access

    Tailored conditioning for hematopoietic stem cell transplantation in children with Mendelian susceptibility to mycobacterial disease: A tale of two pathways for IFN-γ and IL-12 defects

    by Kavitha Ganesan, Minakshi Balwani, Nithya Seshadri, Vijayashree Muthukumar, Krithika Krishnakumar, Anuraag Nalla Reddy, Vidya Krishna, Indira Jayakumar, Ramya Uppuluri, Revathi Raj

    Mendelian susceptibility to mycobacterial disease (MSMD) is a rare group of inborn errors of immunity associated with significant morbidity due to mycobacterial infections. Hematopoietic stem cell transplantation (HSCT) is a curative option; however, persistent infections and high levels of interferon-γ (IFN-γ) create a hostile environment for stem cell proliferation and can mediate graft rejection. We describe the outcome of children with MSMD due to IFN-γ receptor and interleukin-12 (IL-12) defects who underwent HSCT in our unit from December 2015 to December 2023. We collected the data retrospectively from a review of patient charts and analyzed the outcomes. Seven children underwent eight procedures, including four with IFN-γ defects and three with IL-12 defects. The male-to-female ratio was 1.6:1, and the median age at HSCT was 4.5 years. Five received haploidentical HSCT, and two underwent matched family donor transplants; 75% used peripheral blood stem cells. IL-12–deficient cases engrafted well with fludarabine/treosulfan–based conditioning, whereas IFN-γ–deficient cases fared better with fludarabine/treosulfan/thiotepa-based conditioning due to a higher rejection risk. Acute graft-versus-host disease (GVHD) (grade 1–2, skin/gut) occurred in two children: one developed chronic liver GVHD after donor lymphocyte infusion. Cytomegalovirus reactivation occurred in four cases, which responded to ganciclovir or cidofovir. One primary graft failure was rescued with a second HSCT; one secondary graft failure led to death from invasive fungal infection. At a median follow-up of 8 years, the overall survival was 87%. One survivor has ongoing seizures, aggressive behavior, and endocrine dysfunctions requiring supportive care. HSCT is a curative option for children with MSMD. However, we need to understand gene mutation and individualize the approach to preparation and conditioning regimens to help optimize the outcome.

  • Prospective Collaborative Study for Pulse Dexamethasone and Lenalidomide in Relapsed/Refractory Langerhans Cell Histiocytosis (LENDEX‐LCH Study): INPHOG‐HIST‐19‐03 (CTRI/2020/07/026937)

    by Ramya Uppuluri, Manas Kalra, Satyendra Katewa, Vinod Gunasekaran, Nita Radhakrishnan, Chetan Dhamne, Sirisharani Siddaiahgari, Revathi Raj

    Background: The Indian Paediatric Haematology Oncology Group (INPHOG) multicentre study aimed to prospectively analyse the efficacy and safety of lenalidomide and dexamethasone (LENDEX) in children with refractory/relapsed Langerhans cell histiocytosis (LCH). Procedure: The study was a prospective, multicentre study conducted through the INPHOG Histiocytosis Subcommittee. The Clinical Trials Registry of India registration was obtained, and the study was open to recruitment from June 2020 to June 2023. Results: A total of 15 children were included from seven centres in India, median age being 4 years (Range 3–13 years). Thirteen children were diagnosed to have multisystem disease at relapse with involvement of skin, bone and liver; and one child each with multifocal bone disease and single site bone lesion. One child with refractory lung disease had progression after two cycles of LENDEX and was taken off protocol. Four (26%) children achieved CR after six cycles of LENDEX; while eight (53%) children had PR at three and six cycles, with CR at the end of nine cycles of LENDEX. The combination was well tolerated, the most common adverse effects being mild anaemia and myalgia. There were no deaths within the cohort, with a median follow‐up of 24 months (Range 18–48 months). The overall response rate was 73%, with 26% responses at six cycles and 53% at nine cycles of LENDEX. Conclusion: LENDEX is well tolerated and effective in 73% children with relapsed/refractory LCH. Future studies would include nine cycles of LENDEX followed by maintenance for 12 months with 6‐mercaptopurine.

  • Open Access

    Common Variable Immunodeficiency Disorder: A Decade of Insights from a Cohort of 150 Patients in India and the Use of Machine Learning Algorithms to Predict Severity

    by Umair Ahmed Bargir, Priyanka Setia, Mukesh Desai, Chandrakala S, Aparna Dalvi, Shweta Shinde, Maya Gupta, Neha Jodhawat, Amrutha Jose, Mayuri Goriwale, et al.

    Common Variable Immunodeficiency (CVID) is a heterogeneous disorder characterized by impaired antibody production and recurrent infections. In this study we investigated the clinical and immunological features of CVID in Indian patients and develops a machine learning model for predicting disease severity. We retrospectively analyzed 150 patients diagnosed with CVID over a decade at a tertiary care center in India. The median age of diagnosis was 18 years, with a male predominance (62%). The majority of patients (66.6%) had a severe phenotype, with recurrent respiratory tract infections being the most common clinical manifestation (84.2%). Gastrointestinal complications were observed in 45% of patients, while autoimmune manifestations were seen in 21%. All patients exhibited hypogammaglobulinemia. IgA levels varied, with 7.8% normal and 14.5% undetectable. IgM levels were decreased in 85.5% of patients. B-cell analysis revealed 64.4% had reduced class-switched memory B cells, with 21.7% showing very low levels. Nine adult patients presented with late-onset combined immunodeficiency. Genetic testing, performed on 52 patients, identified underlying monogenic causes in 29 pediatric and 15 adult patients. LRBA deficiency was the most common genetic defect, found in seven pediatric and three adult patients. We developed a novel machine learning-based severity prediction model for CVID patients, utilizing readily available lymphocyte subsets, class-switched memory B cell counts, and serum immunoglobulin levels to provide an accessible and robust tool for predicting disease severity using Ameratunga’s clinical severity score. Random Forest outperformed other models across all metrics, achieving an accuracy of 0.853 (95% CI: 0.840–0.866). Feature importance analysis across all models identified Th-Tc ratio, CD19, and IgM levels as the most influential predictors for severity prediction. Our study highlights the diverse clinical and immunological features of CVID in Indian patients, emphasizing the need for early diagnosis and individualized management strategies. The machine learning model developed using commonly available immune parameters provide a robust tool for predicting disease severity, potentially guiding treatment strategies to improve patient outcomes.


  • Open Access

    Outcomes of COVID-19 in children with cancer – Report from the Indian Pediatric Oncology Group (InPOG) COVID-19 registry in India

    by Revathi Raj, Ramya Uppuluri, Badira Parambil, Nidhi Dhariwal, Sidharth Totadri, Leni Grace Mathew, Venkatraman Radhakrishnan, Abhishek Charan, Satya Prakash Yadav, Amita Mahajan, et al.


  • Open Access

    The impact of COVID-19 in children post hematopoietic stem cell transplantation: Experience from a pediatric transplant unit in India

    by Rumesh Chandar, Venkateswaran Vellaichamy Swaminathan, Satishkumar Meena, Harika Varla, Ramya Uppuluri, Revathi Raj


  • Open Access

    The first report of allogeneic haematopoietic stem cell transplantations for bone marrow failure performed in Sri Lanka

    by Wasanthi Wickramasinghe, Ruwangi Dissanayake, Revathi Raj, Lallindra Gooneratne


  • Open Access

    Multicenter Outcome of Hematopoietic Stem Cell Transplantation for Primary Immune Deficiency Disorders in India

    by Revathi Raj, Fouzia N. Aboobacker, Satya Prakash Yadav, Ramya Uppuluri, Sunil Bhat, Dharma Choudhry, Vikas Dua, Gaurav Kharya, Neha Rastogi, Mansi Sachdev, et al.

    Background: Hematopoietic stem cell transplantation (HSCT) is the curative option for many primary immune deficiency disorders (PID). In the last 5 years, increased awareness, availability of diagnostics based on flow cytometry, genetic testing, improved supportive care, use of reduced toxicity conditioning, and success of haploidentical donor HSCT have improved access to HSCT for children with PID in India. We present results on children with PID who underwent HSCT across India and the factors that influenced outcome. Patients and Methods: We collected retrospective data on the outcome of HSCT for PID from seven centers. We analyzed the impact of the type of PID, conditioning regimen, time period of HSCT- before or after January 2016, graft versus host disease prophylaxis, cause of mortality and overall survival. Results: A total of 228 children underwent HSCT for PID at a median age of 12 months (range, 1 to 220 months) with a median follow up of 14.4 months. Infants accounted for 51.3% of the cohort and the male female ratio was 3:1. SCID (25%) and HLH (25%) were the more frequent diagnoses. Matched family donor was available in 36.4% and 44.3% children had a haploidentical HSCT. Reduced and myeloablative conditioning regimens were used with 64% children receiving a treosulfan based conditioning regimen. Peripheral blood stem cells were the predominant graft source at 69.3%. The survival in infants (60.2%) was inferior to children aged over 1 year (75.7% p value = 0.01). Children with Wiskott Aldrich syndrome (74.3%) and chronic granulomatous disease (82.6%) had the best outcomes. The survival was superior in children receiving HSCT from a matched sibling (78%) versus an alternate donor HSCT (61% p value = 0.04). In the cohort transplanted after January 2016 survival improved from 26.8% to 77.5% (p value = 0.00). Infection remains the main cause of mortality at in over 50% children. The 5-year overall survival rate was 68%. Conclusion: Survival of children with PID undergoing HSCT in India has improved dramatically in last 5 years. Alternate donor HSCT is now feasible and has made a therapeutic option accessible to all children with PID.


  • Open Access

    Preliminary Experience of Treating Children and Young Adults With Image-Guided Proton Beam Therapy in India

    by Srinivas Chilukuri, Nagarjuna Burela, Ramya Uppuluri, D. Indumathi, Sapna Nangia, Pankaj Kumar Panda, Dayananda Sharma Shamurailatpam, Revathi Raj, Thirumalai Raja, Rakesh Jalali

    PURPOSE: Proton beam therapy (PBT) has been a preferred modality in pediatric malignancies requiring radiotherapy. We report our preliminary experience of treating consecutive patients younger than 25 years with image-guided pencil beam scanning PBT from the first and only center on the Indian subcontinent. METHODS: Patients were selected for PBT on the basis of a multidisciplinary tumor board decision. Patient demographic data, as well as tumor and treatment-related characteristics of the cohort, were captured. Patient and treatment-related factors and their association with acute toxicities were analyzed using univariable and multivariable analyses. RESULTS: Forty-seven patients (27 with CNS and 20 with non-CNS tumors) with a median age of 9 years (range, 2-25 years) were evaluated. Most common diagnoses were ependymoma, rhabdomyosarcoma, and glioma. Seventy-seven percent of patients traveled more than 500 km, and 70% of them lived in metropolitan cities. Forty-nine percent of patients had recurrent disease at presentation, and 15% had received a previous course of radiation. The median dose delivered was 54.8 cobalt gray equivalents (range, 40.0-70.4 cobalt gray equivalents) to a median clinical target volume of 175 mL (range, 18.7-3,083.0 mL), with 34% of patients requiring concurrent chemotherapy (CCT). Acute grade 2 and grade 3 dermatitis, mucositis, and hematologic toxicity was noted in 45% and 2%, 34% and 0%, and 38% and 30% of patients, respectively. Grade 2 fatigue was noted in 26% of patients. On multivariable analysis, for CNS tumors, both CCT and craniospinal irradiation were independently associated with ≥ 2 grade hematologic toxicity, whereas among non-CNS tumors, a clinical target volume > 150 mL was associated with ≥ 2 grade fatigue, head and neck irradiation was associated with ≥ 2 grade mucositis, and CCT was associated with grade ≥ 2 hematologic toxicity. CONCLUSION: This study demonstrates safe implementation of a PBT program for children and young adults on the Indian subcontinent. Image-guided pencil beam scanning PBT in judiciously selected patients is feasible and can be delivered with acceptable acute toxicities.